Physician profile
Renee Hill
NPI 1639268634
$3,920.18
in general payments reported to CMS, 2019-2025
20 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $605 · 2021: $584 · 2022: $524 · 2023: $351 · 2024: $717 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,424.66 | 2021-2025 | |
| Allergan, INC. | $667.69 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $415.55 | 2019-2025 | Rexulti, Abilify Mycite |
| Sunovion Pharmaceuticals INC. | $293.38 | 2019-2022 | |
| Axsome Therapeutics, INC. | $277.41 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $190.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.19 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $98.56 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $86.71 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $70.74 | 2020-2024 | Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $42.53 | 2022-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $37.81 | 2024 | Ingrezza |
| Lundbeck LLC | $35.14 | 2019 | |
| Tris Pharma INC | $29.77 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $24.50 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $22.08 | 2020 | |
| Alkermes, INC. | $20.79 | 2019 | |
| Eisai INC. | $20.20 | 2022 | |
| Boston Scientific Corporation | $14.92 | 2022 | |
| Neos Therapeutics, LP | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.